Pharmaceutical companies pledged over $480 billion for U.S.-based production, including 22 new manufacturing sites and 44,000 jobs, driven by tariff threats and Section 232 investigations.2
Key players like Eli Lilly ($27B for APIs and injectables), Johnson & Johnson ($2B biologics plant in North Carolina), UCB ($2B biologics plant in Atlanta), AstraZeneca, Novartis, Roche, and Sanofi announced major 2025 investments.245
Motivations include supply chain vulnerabilities (72% of U.S. API suppliers overseas), drug shortages up 30% from 2021-2022, national security risks, and incentives like IRA tax credits up to 30%.1
Challenges involve securing skilled labor, regulatory compliance, governance, and distinguishing greenfield vs. brownfield projects; immediate production gains unlikely.124
Reshoring efforts surged in 2025 with $170B+ in projects and global output front-loading in response to U.S. tariff threats.35
Sources:
1. https://www.actalentservices.com/en/insights/articles/future-of-pharma-insourcing-and-reshoring-in-a-booming-market
2. https://www.thinkglobalhealth.org/article/tracking-pharmas-progress-on-u-s-onshoring
3. https://www.packagingdigest.com/pharma-medical/us-pharma-reshoring-boom-surpasses-170-billion-in-new-projects
4. https://www.grantthornton.com/insights/articles/life-sciences/2025/assessing-reshoring-considerations-for-life-sciences-companies
5. https://omny.fm/shows/the-top-line/an-update-on-the-pharma-industry-s-reshoring-effort